Company
TransMedics Group, Inc.
Headquarters: Andover, MA, United States
Employees: 148
CEO: Dr. Waleed H. Hassanein
Market Cap
$2.10 Billion
USD as of Jan. 1, 2025
TransMedics Group, Inc. Categories
United States Healthcare Medical DevicesUnited States Healthcare United States Medical Devices
Top Competitors by Market Capitalization
Industry: Medical Devices
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $401.1 M |
| EBITDA | $64.3 M |
| Gross Profit TTM | $238.0 M |
| Profit Margin | 8.14% |
| Operating Margin | 3.61% |
| Quarterly Revenue Growth | 63.70% |
Stocks & Indices
TransMedics Group, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TMDX wb_incandescent